bevacizumab

Summary

Summary: An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF RECEPTORS and helps prevent the proliferation of blood vessels.

Top Publications

  1. Wong E, Huberman M, Lu X, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol. 2008;26:5649-50 pubmed publisher
  2. Żarnowski T, Tulidowicz Bielak M. Topical bevacizumab is efficacious in the early bleb failure after trabeculectomy. Acta Ophthalmol. 2011;89:e605-6 pubmed publisher
  3. Sherman J, Aregawi D, Lai A, Fathallah Shaykh H, Bierman P, Linsky K, et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology. 2009;73:1924-6 pubmed publisher
  4. Grover S, Gupta S, Sharma R, Brar V, Chalam K. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol. 2009;93:273-4 pubmed publisher
  5. Shimura M, Yasuda K. Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease. Br J Ophthalmol. 2010;94:381-3 pubmed publisher
  6. Kim Y, Mishima M, Miyagawa Hayashino A. Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab. J Thorac Oncol. 2010;5:1107-8 pubmed publisher
  7. Grunewald T, Damke L, Maschan M, Petrova U, Surianinova O, Esipenko A, et al. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol. 2010;21:1733-4 pubmed publisher
  8. Benoit A, Ducray F, Cartalat Carel S, Psimaras D, Ricard D, Honnorat J. Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. J Neurol. 2011;258:328-9 pubmed publisher
  9. Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol. 2009;20:393-4 pubmed publisher

More Information

Publications62

  1. Bose P, Holter J, Selby G. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009;360:2143-4 pubmed publisher
  2. Gerstner E, Frosch M, Batchelor T. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2010;28:e91-3 pubmed publisher
  3. Van Cutsem E, Lambrechts D, Prenen H, Jain R, Carmeliet P. Lessons from the adjuvant bevacizumab trial on colon cancer: what next?. J Clin Oncol. 2011;29:1-4 pubmed publisher
  4. Jeong S, Sagong M, Chang W. Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. BMC Ophthalmol. 2017;17:25 pubmed publisher
    ..The authors report a case of AAC that occurred immediately after administering intravitreal bevacizumab to treat branch retinal vein occlusion (BRVO)...
  5. Matsuda M, Krempel P, Marquezini M, Sholl Franco A, Lameu A, Monteiro M, et al. Cellular stress response in human Müller cells (MIO-M1) after bevacizumab treatment. Exp Eye Res. 2017;160:1-10 pubmed publisher
    b>Bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, is widely used in the treatment of retinal vascular diseases...
  6. Khurana R, Chang L, Porco T. Incidence of Presumed Silicone Oil Droplets in the Vitreous Cavity After Intravitreal Bevacizumab Injection With Insulin Syringes. JAMA Ophthalmol. 2017;135:800-803 pubmed publisher
    Intravitreal bevacizumab is a frequently used antivascular endothelial growth factor medication in the United States, but its off-label use is associated with risks associated with the compounding preparation...
  7. Pineda E, Salud A, Vila Navarro E, Safont M, Llorente B, Aparicio J, et al. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumour Biol. 2017;39:1010428317705509 pubmed publisher
    Despite initial responsiveness, acquired resistance to both bevacizumab and chemotherapy in metastatic colorectal cancer is universal...
  8. Terada M, Sugiura H, Yoshimoto N, Nishikawa S, Ito Y, Kawaguchi Y, et al. [Three Poor Performance Status(PS)Cases of Metastatic Breast Cancer Controlled with Adjustment of Dosing Interval and Dosage of Bevacizumab and Paclitaxel]. Gan To Kagaku Ryoho. 2017;44:591-593 pubmed
    A standard symptomatic therapy regimen of bevacizumab(BV)plus paclitaxel(PTX)was planned for use in 3 cases of metastatic breast cancer...
  9. Ocana A, Amir E, Vera F, Eisenhauer E, Tannock I. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol. 2011;29:254-6 pubmed publisher
  10. Kwiatkowski S, Guerrero P, Hirota S, Chen Z, Morales J, Aghi M, et al. Neuropilin-1 modulates TGF? signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy. PLoS ONE. 2017;12:e0185065 pubmed publisher
    ..Anti-angiogenic agents such as the vascular endothelial growth factor-A (VEGF-A) blocking antibody bevacizumab yield short-term benefits to patients due to blood vessel regression and stabilization of vascular permeability...
  11. De Marinis F, Bidoli P, Luciani A, Amoroso D, Tonini G, Bertolini A, et al. EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer. Anticancer Res. 2017;37:2457-2464 pubmed
    ..Patients (?70 years) were randomly assigned to bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2 i.v. on days 1-8) (arm A) or bevacizumab (7...
  12. Bressler S, Liu D, Glassman A, Blodi B, Castellarin A, Jampol L, et al. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135:558-568 pubmed publisher
    ..To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME...
  13. Sengupta S, Pan U. Combined branch retinal vein and branch retinal artery occlusion - clinical features, systemic associations, and outcomes. Indian J Ophthalmol. 2017;65:238-241 pubmed publisher
    ..eyes were treated with angiography-guided sectoral laser photocoagulation, and three eyes required intravitreal bevacizumab due to macular edema or retinal neovascularization...
  14. CRIM A, Rowland M, Ruskin R, Dvorak J, Greenwade M, Walter A, et al. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017;146:268-272 pubmed publisher
    ..IP CT appears well tolerated and effective among select older patients and is likely under-utilized outside of clinical trials. ..
  15. Puchner M, Hans V, Harati A, Lohmann F, Glas M, Herrlinger U. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010;21:2445-6 pubmed publisher
  16. Virgili G, Parravano M, Evans J, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:CD007419 pubmed publisher
    ..as interventions of direct interest for practice: aflibercept and ranibizumab, used on-label; and off-label bevacizumab.We collected data on three efficacy outcomes (gain of 15 or more Early Treatment Diabetic Retinopathy Study (..
  17. Okuda T, Tasaki T, Nakata S, Yamashita K, Yoshioka H, Izumoto S, et al. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma. Anticancer Res. 2017;37:3871-3876 pubmed
    ..Although the VEGF inhibitor bevacizumab was recently highlighted as the second-line drug for GBM treatment, GBMs often recur even with bevacizumab ..
  18. Constantinidou A, Jones R, Olmos D, Thway K, Fisher C, Al Muderis O, et al. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012;51:550-4 pubmed publisher
  19. Blakeley J, Schreck K, Evans D, Korf B, Zagzag D, Karajannis M, et al. Clinical response to bevacizumab in schwannomatosis. Neurology. 2014;83:1986-7 pubmed publisher
  20. Gore E, Currey A, Choong N. Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. J Thorac Oncol. 2009;4:1590-1 pubmed publisher
  21. Mahase S, Rattenni R, Wesseling P, Leenders W, Baldotto C, Jain R, et al. Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. Am J Pathol. 2017;187:940-953 pubmed publisher
    ..Juxtaposing recent studies on well-established resistance pathways with that of emerging mechanisms highlights the overall complexity of GBM treatment resistance while also providing direction for further investigation. ..
  22. Grabosch S, Tseng G, Edwards R, Lankes H, Moore K, Odunsi K, et al. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017;146:137-145 pubmed publisher
    ..Flow cytometry does not adequately capture biomarker fluctuations. As a proof of principle study, this trial provides evidence that sampling the peritoneal cavity can be adapted for biomarker analysis. ..
  23. Sugimoto M, Ichio A, Nunome T, Kondo M. Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol. Medicine (Baltimore). 2017;96:e6406 pubmed publisher
    To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME).Retrospective, single-center study...
  24. Eisterer W, Piringer G, de Vries A, Ofner D, Greil R, Tschmelitsch J, et al. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. Anticancer Res. 2017;37:2683-2691 pubmed
    To evaluate feasibility and safety of neoadjuvant chemotherapy with capecitabine, oxaliplatin and bevacizumab followed by concomitant standard chemoradiation and surgical resection in patients with high-risk locally advanced rectal ..
  25. Lee J, Bae H, Lee S, Seong G, Kim C. Effect of Anti-vascular Endothelial Growth Factor Antibody on the Survival of Cultured Retinal Ganglion Cells. Korean J Ophthalmol. 2017;31:360-365 pubmed publisher
    ..01, 0.1, and 1 mg) using bevacizumab as the anti-VEGF antibody...
  26. Duwe G, Knitter S, Pesthy S, Beierle A, Bahra M, Schmelzle M, et al. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. Eur J Surg Oncol. 2017;43:1668-1681 pubmed publisher
    ..Administration of bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF), has been reported to improve response of CLM to ..
  27. Xue Y, Martelotto L, Baslan T, Vides A, SOLOMON M, Mai T, et al. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nat Med. 2017;23:929-937 pubmed publisher
    ..Treatments that impose the highest fitness threshold will likely prevent the evolution of resistance-causing alterations and, thus, merit testing in patients. ..
  28. Katoh M, Takeda N, Arimoto T, Abe H, Oda K, Osuga Y, et al. Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil. Int Heart J. 2017;58:803-805 pubmed publisher
    b>Bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF)-A, is currently used to treat patients with ovarian or colon cancer...
  29. Kachaamy T, Gupta D, Edwin P, Vashi P. Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study. PLoS ONE. 2017;12:e0176899 pubmed publisher
    ..In this retrospective study, the rate of endoscopy-related AEs in patients on AAs appears to be low when performed in specialized cancer centers. However, future prospective studies are needed to confirm this finding. ..
  30. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, et al. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011;29:e572-5 pubmed publisher
  31. Fraioli F, Vetere S, Anile M, Venuta F. Computed tomography perfusion: a new method to evaluate response to therapy in lung cancer. J Thorac Oncol. 2011;6:1599-600 pubmed publisher
  32. Scott I, VanVeldhuisen P, Ip M, Blodi B, Oden N, King J, et al. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. JAMA Ophthalmol. 2017;135:639-649 pubmed publisher
    ..Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) therapy may provide information useful in counseling patients...
  33. de Cogan F, Hill L, Lynch A, Morgan Warren P, Lechner J, Berwick M, et al. Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides. Invest Ophthalmol Vis Sci. 2017;58:2578-2590 pubmed publisher
    ..CPP toxicity was investigated in cell cultures. Ivit concentrations of ranibizumab and bevacizumab after topical administration were measured using ELISA...
  34. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol. 2009;20:966-7; author reply 967 pubmed publisher
  35. Dashti Khavidaki S, Abdollahi M. Intravitreal administration of bevacizumab: pros and cons. Daru. 2015;23:27 pubmed publisher
  36. Fleming N, Coleman R, Tung C, Westin S, Hu W, Sun Y, et al. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017;147:41-46 pubmed publisher
    To assess the tolerability and efficacy of bevacizumab with carboplatin and weekly paclitaxel as first-line adjuvant therapy for advanced stage ovarian cancer...
  37. Field K, Phal P, Fitt G, Goh C, Nowak A, Rosenthal M, et al. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET). Cancer. 2017;123:3576-3582 pubmed publisher
    b>Bevacizumab has been associated with prolonged progression-free survival for patients with recurrent glioblastoma; however, not all derive a benefit...
  38. Ishii F, Yoshida Y, Yamauchi Y, Aisu N, Kojima D, Mera T, et al. Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated ?? T-cells. Anticancer Res. 2017;37:3933-3939 pubmed
    ..2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded ?? T-lymphocytes as first-line chemoimmunotherapy were included...
  39. Fornaro L, Crea F, Masi G, Paolicchi E, Loupakis F, Graziano F, et al. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Ann Oncol. 2012;23:1370-1 pubmed publisher
  40. Mehta H, Fraser Bell S, Yeung A, Campain A, Lim L, Quin G, et al. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. Br J Ophthalmol. 2016;100:1000-1004 pubmed publisher
    To report the effect of bevacizumab versus dexamethasone on hard exudates (HEX) in diabetic macular oedema (DME)...
  41. Botta C, Misso G, Martino E, Pirtoli L, Cusi M, Tassone P, et al. The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. Cell Death Dis. 2016;7:e2299 pubmed publisher
  42. Mizota A, Shitara K, Fukui T. Bevacizumab chemotherapy for pulmonary epithelioid hemangioendothelioma with severe dyspnea. J Thorac Oncol. 2011;6:651-2 pubmed publisher
  43. Xiong Y, Ren L, Wang Z, Huang X, Zhou Y. The role of angiogenesis inhibitors re-challenge in colorectal cancer previously treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2017;21:1489-1494 pubmed
    ..AIs) re-challenge in the treatment of metastatic colorectal cancer (CRC) who previously treated with bevacizumab has not been established yet...
  44. Sato F, Toi M. [Molecular targeted therapy and genomic evolution of breast cancer]. Nihon Rinsho. 2015;73:1364-72 pubmed
    ..In this article, latest knowledge regarding breast cancer genome, especially in terms of 'evolution', is summarized. ..
  45. Mahfouz N, Tahtouh R, Alaaeddine N, El Hajj J, Sarkis R, Hachem R, et al. Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1? and VEGF receptors. PLoS ONE. 2017;12:e0179202 pubmed publisher
    ..b>Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) being used for this purpose...
  46. Hettema W, Wynne C, Lang B, Altendorfer M, Czeloth N, Lohmann R, et al. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Expert Opin Investig Drugs. 2017;26:889-896 pubmed publisher
    This Phase I trial (INVICTAN®-1) evaluated three-way bioequivalence and safety of BI 695502 a bevacizumab biosimilar candidate, and reference product bevacizumab from two sources (US-approved Avastin®, Genentech; EU-approved Avastin, ..
  47. Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer. 2012;19:L1-4 pubmed publisher
  48. Lucatto L, Magalhães Júnior O, Prazeres J, Ferreira A, Oliveira R, Moraes N, et al. Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion. Arq Bras Oftalmol. 2017;80:97-103 pubmed publisher
    To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with ..
  49. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?. Br J Ophthalmol. 2012;96:1-2 pubmed publisher
  50. Lim L, Cheung C, Mitchell P, Wong T. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?. Am J Ophthalmol. 2011;152:329-331 pubmed publisher
  51. Castillo J, Aleman I, Rush S, Rush R. Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation. Am J Ophthalmol. 2017;183:1-10 pubmed publisher
    To assess the optimal interval of preoperative intravitreal bevacizumab (IVB) administration in diabetic subjects undergoing pars plana vitrectomy (PPV) for severe manifestations of active proliferative diabetic retinopathy (PDR)...
  52. Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. JAMA Oncol. 2017;3:e170278 pubmed publisher
    The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer...
  53. Mizushima T, Fukunaga M, Sueda T, Ikeda M, Kato T, Kim H, et al. Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy. Cancer Chemother Pharmacol. 2017;80:81-90 pubmed publisher
    We aimed to determine the recommended dose for bi-weekly XELIRI plus bevacizumab for second-line chemotherapy and examined its safety and efficacy in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line ..